Sarepta Therapeutics (SRPT) Receivables (2010 - 2026)

Sarepta Therapeutics' Receivables history runs 17 years deep, the most recent figure standing at $531.2 million for Q1 2026.

• In Q1 2026, Receivables fell 25.66% year-over-year to $531.2 million; the TTM figure through Mar 2026 stood at $531.2 million (down 25.66% YoY), while the FY2025 annual figure was $502.3 million, down 21.09% from the prior year.
• Receivables was $531.2 million for Q1 2026 at Sarepta Therapeutics, up from $502.3 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $714.6 million in Q1 2025 to a low of $195.9 million in Q1 2022.
• Historically, Receivables has averaged $414.2 million across 5 years, with a median of $408.9 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Receivables surged 74.75% in 2025, then dropped 25.66% in 2026.
• A 5-year view of Receivables shows it stood at $256.4 million in 2022, then soared by 67.76% to $430.1 million in 2023, then surged by 48.0% to $636.6 million in 2024, then dropped by 21.09% to $502.3 million in 2025, then climbed by 5.75% to $531.2 million in 2026.
• The last three Receivables figures came in at $531.2 million (Q1 2026), $502.3 million (Q4 2025), and $524.4 million (Q3 2025), per Business Quant data.